Growth Metrics

BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $930.7 million.

  • BioNTech SE's Current Deferred Revenue rose 12484.71% to $930.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $930.7 million, marking a year-over-year increase of 12484.71%. This contributed to the annual value of $315.1 million for FY2024, which is 2650.26% down from last year.
  • Latest data reveals that BioNTech SE reported Current Deferred Revenue of $930.7 million as of Q3 2025, which was up 12484.71% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Current Deferred Revenue registered a high of $1.1 billion during Q2 2025, and its lowest value of $48.9 million during Q1 2023.
  • Moreover, its 5-year median value for Current Deferred Revenue was $356.1 million (2021), whereas its average is $429.6 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 7728.68% in 2023, then skyrocketed by 74166.63% in 2024.
  • Over the past 5 years, BioNTech SE's Current Deferred Revenue (Quarter) stood at $212.9 million in 2021, then tumbled by 63.05% to $78.7 million in 2022, then soared by 445.08% to $428.8 million in 2023, then decreased by 26.5% to $315.1 million in 2024, then soared by 195.33% to $930.7 million in 2025.
  • Its last three reported values are $930.7 million in Q3 2025, $1.1 billion for Q2 2025, and $309.8 million during Q1 2025.